Diseases

Progressive supranuclear palsy

Progressive supranuclear palsy (PSP) is a neurodegenerative disease, which means it is a chronic condition that worsens over time as damage builds up in parts of the nervous system. It affects the central nervous system, causing problems with movement, balance, and eye control^1-3. PSP is not very common, affecting between 5.8 and 6.5 people per 100,000². Its average age of onset is 65 years and it tends to be slightly more common in men^1-3.

Two medical professionals carefully analyze images from brain scans and X-rays on computer screens inside a lighted office.

The exact cause of PSP is not fully understood, but it is related to abnormal tau protein accumulation and neuronal loss⁴. Tau protein is a special protein in the brain that helps keep brain cells healthy by stabilizing their structure¹.

A young hand gently holds the arm of an older woman with gray hair.

Close-up of joined hands holding each other tightly in a gesture of support, comfort or complicity.

The abnormal accumulation of tau causes the death of neurons, leading to the characteristic symptoms of the disease: difficulties in maintaining balance and changes in the way of walking, problems with eye control such as difficulty looking down, cognitive problems, and difficulties with speaking and swallowing, among others^1-3.

Although there is currently no cure for PSP, there are treatment options that can help relieve symptoms^1-3. Physical and occupational therapy also play an important role in improving mobility and quality of life. In addition, emotional and social support is essential for affected individuals and their families^1-3.

1. Coughlin DG, Litvan I. Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism Relat Disord. 2020 Apr;73:105-116. doi: 10.1016/j.parkreldis.2020.04.014. Epub 2020 May 25.

2. Agarwal S, Gilbert R. Progressive Supranuclear Palsy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at:https://www.ncbi.nlm.nih.gov/books/NBK526098/

3. Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021; 21(5):376-383. DOI: 10.1136/practneurol-2020-002794

FNP 223 – Progressive Supranuclear Palsy (PSP)

Phase 2

FNP223-CT-2301 PROSPER

Neurological disorders
Randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and pharmacokinetics of FNP-223 (oral formulation) for the treatment of progressive supranuclear palsy (PSP).

Ongoing

View All Clinical Trials